Sign in
CompletedPhase 4

Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population

Key facts

Who runs it
University of Oulu
Where
Finland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
68 people enrolled
Started
1 Feb 2017
Ended
18 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dexmedetomidine
  • Sedatives/Hypnotics,Other
Record updated
20 December 2023

Who can take part

Age
1 year to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Patient age between ages 1year to 18 years
  • A joint inflammation in 1-5 joints needing intra-articular corticosteroid injection diagnosed by pediatric rheumatologist

Who cannot take part

  • Patients under the age of 1year and over the age of 18years are excluded as well as patients needing injection therapy to more than 5 joints

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main objective of this study is to evaluate the effectivity of intranasal dexmedetomidine sedation during intra-articular injection therapy. Intranasal dexmedetomidine is compared with dinitrous oxide (N2O) which has already been proven safe and effective sedation method during painful procedures in pediatric patients.

Read full original descriptionShow less

In earlier studies the median VAS during intra-articular corticosteroid injections with patients receiving nitrous oxide has been 3 (Uziel et al 2008). Study hypothesis is that with intranasal dexmedetomidine sedation the VAS pain levels will be 1 unit lower.

The 2 groups in the trial

  • Intranasal dexmedetomidineTreatment being tested

    Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.

    Treatment: Dexmedetomidine and Sedatives/Hypnotics,Other

  • Nitrous oxide inhalationExisting treatment, for comparison

    Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.

    Treatment: Dexmedetomidine and Sedatives/Hypnotics,Other

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
20 December 2023